Aurobindo Pharma Ltd
NSE:AUROPHARMA

Watchlist Manager
Aurobindo Pharma Ltd Logo
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Watchlist
Price: 1 223.7 INR 0.55% Market Closed
Market Cap: 710.7B INR
Have any thoughts about
Aurobindo Pharma Ltd?
Write Note

Aurobindo Pharma Ltd
Cash Interest Paid

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aurobindo Pharma Ltd
Cash Interest Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Interest Paid CAGR 3Y CAGR 5Y CAGR 10Y
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Cash Interest Paid
â‚ą2.5B
CAGR 3-Years
73%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Cash Interest Paid
â‚ą2.3B
CAGR 3-Years
20%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Cash Interest Paid
â‚ą442.1m
CAGR 3-Years
-25%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Cash Interest Paid
â‚ą2.2B
CAGR 3-Years
26%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Cash Interest Paid
â‚ą3.1B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
M
Mankind Pharma Ltd
NSE:MANKIND
Cash Interest Paid
â‚ą261.7m
CAGR 3-Years
15%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aurobindo Pharma Ltd
Glance View

Market Cap
717B INR
Industry
Pharmaceuticals

Aurobindo Pharma Ltd., a prominent player in the global generic pharmaceutical market, began its journey in 1986 with a vision to make high-quality medicines accessible to patients around the world. Over the years, the company has transformed into a diversified pharmaceutical powerhouse, producing a wide range of generic formulations, active pharmaceutical ingredients (APIs), and complex generics. Headquartered in Hyderabad, India, Aurobindo leverages robust research and development capabilities, along with an extensive manufacturing footprint that spans several countries, allowing it to cater to diverse markets, including the United States and Europe. With a commitment to quality and regulatory compliance, Aurobindo's products cover multiple therapeutic areas, including anti-retrovirals, antibiotics, cardiovascular, and central nervous system disorders, making it a well-regarded name in the industry. For investors, Aurobindo Pharma represents an attractive opportunity, given its consistent revenue growth and strategic focus on innovation. The company's investment in technology and its ability to navigate stringent regulatory landscapes enable it to maintain a competitive edge in the generics sector. Furthermore, Aurobindo's expanding portfolio of complex generics positions it to capture higher margins in the marketplace, while its strong presence in emerging markets ensures ongoing demand for its offerings. As the global healthcare landscape continues to evolve, Aurobindo Pharma's adaptability and commitment to sustainable growth make it a compelling choice for those looking to invest in a resilient and forward-thinking pharmaceutical enterprise.

AUROPHARMA Intrinsic Value
1 081.41 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Aurobindo Pharma Ltd's Cash Interest Paid?
Cash Interest Paid
2.5B INR

Based on the financial report for Jun 30, 2024, Aurobindo Pharma Ltd's Cash Interest Paid amounts to 2.5B INR.

What is Aurobindo Pharma Ltd's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
73%

Over the last year, the Cash Interest Paid growth was 125%. The average annual Cash Interest Paid growth rates for Aurobindo Pharma Ltd have been 73% over the past three years .

Back to Top